United Parcel Service is leaning into prescription drug deliveries as a strategic counterweight to softer demand in conventional parcel segments, CEO Carol Tome said in a recent interview. The company expects the benefits of that focus to be more visible in the second half of the year, even as the U.S.-Israeli conflict with Iran clouds the wider economic picture.
Tome highlighted the distinctive characteristics of healthcare logistics - often involving secure, rapid transport of temperature-sensitive medicines and radioactive treatments - and said they tend to be less cyclical than sectors such as retail, housing or manufacturing. "There have been lots of challenges over the past several years - high inflation, contractions in markets - but healthcare continues to grow," she said. "I would argue that healthcare is pretty recession-proof."
Prescription drug shipments have become a cornerstone of UPS' multi-year turnaround plan. The strategy is to carry fewer packages overall but to shift the mix toward deliveries with higher profit margins. That pivot is designed to offset the drag from declining low-value e-commerce volume and to improve operating leverage as network reconfiguration and automation initiatives finish.
Sector context within UPS' results underscores the approach. The company reported its first $3 billion healthcare revenue quarter in its history and has taken market share in the segment since 2021, according to Tome. UPS posted $11.2 billion in healthcare revenue for 2025, roughly 13% of consolidated revenue, and healthcare made up more than 14% of consolidated revenue in the first quarter of 2026. As low-margin package volume falls away this year, the proportion of higher-margin business should rise, lowering operating costs and amplifying earnings growth, management says.
Tome and other executives have pointed to the margin differential across shipment types as a core rationale for the pivot. She noted that shipments of very expensive medicines can carry margins in the mid-to-high-teens, while e-commerce parcel margins sit in the very low single digits. Those pricing dynamics make complex healthcare logistics an attractive target for parcel operators seeking to protect profitability.
Within the broader outsourced healthcare logistics market, which is currently dominated by DHL Group, UPS is pushing to expand its footprint. The industry is substantial - on the order of more than $80 billion - and some analysts anticipate significant expansion in the years ahead. Even so, UPS is now gaining ground against DHL and outpacing rival FedEx in several healthcare subsegments, according to market observers.
While healthcare is a key growth area, not all parts of the business are immune to economic swings. Analysts are monitoring home deliveries of GLP-1 weight-loss drugs, which are paid for directly by consumers rather than insurers and therefore could be more vulnerable if a downturn reduces discretionary spending.
Geopolitical risks tied to the Iran conflict are already affecting costs. Tome said UPS' base business is holding up in spite of sharply higher fuel prices tied to the virtual closure of the Strait of Hormuz, cost pressure that is pinching consumer and corporate budgets. Elevated fuel and related transport costs are an input-cost headwind that could affect margins if sustained.
The company has undertaken a number of structural changes under Tome's "better, not bigger" strategy, a program that began after she took the helm in June 2020 as the first outsider CEO in UPS' more-than-100-year history. Management has reduced the share of revenue from its largest e-commerce customer, trimming Amazon's proportion of UPS volume from more than 13% at its peak to 8.8% in the latest quarter, while simultaneously making targeted acquisitions to broaden its healthcare capabilities.
To align capacity with the new mix of business, UPS has closed facilities and reduced headcount, including among union delivery drivers. The shift also included surrendering its value-priced Ground Saver product to the U.S. Postal Service, a move executives tied to changes in U.S. tariff policy that curtailed millions of low-value "de minimis" imports shipped from China-linked sellers such as Temu and Shein.
Investment in automation and tracking upgrades at major hubs has been a parallel priority. Management says much of that modernization is nearing completion, and that the resulting efficiency gains will save the company billions in operating costs, creating an inflection point for profitability. Stifel analyst Bruce Chan summarized the progress bluntly in a client note titled: "Home Stretch: Heaviest Lift of Transformation Complete ... Now for the Benefits to Materialize."
The company faces a balancing act: converting operational improvements and a higher-margin business mix into sustainable profit growth, while navigating external pressures such as fuel inflation and geopolitical uncertainty. For now, UPS is positioning healthcare logistics as a durable source of revenue and margin expansion that could help insulate the business if global economic conditions weaken.
Summary
UPS is accelerating its push into higher-margin healthcare deliveries, including prescription drugs that require specialized handling. CEO Carol Tome says this business should help offset weakness in lower-margin e-commerce volumes and that meaningful benefits are expected in the second half of the year. The strategy is supported by network reconfiguration, automation upgrades and targeted acquisitions, but faces risks from rising fuel costs and consumer-sensitive drug deliveries.
Key points
- Healthcare logistics provide higher margins and greater recession resistance than traditional retail and manufacturing parcel segments, supporting UPS' profitability goals.
- UPS reported its first $3 billion healthcare revenue quarter, with $11.2 billion in healthcare revenue for 2025 and healthcare representing more than 14% of consolidated revenue in Q1 2026.
- Network automation, facility rationalization and a smaller share of low-margin e-commerce volume should lower operating costs and amplify earnings as the transformation completes.
Risks and uncertainties
- Geopolitical friction with Iran has pushed fuel prices higher due to the effective closure of the Strait of Hormuz - a cost pressure that could squeeze margins for carriers and raise transport expenses for customers.
- Home deliveries of GLP-1 weight-loss drugs are paid directly by consumers and therefore remain exposed to discretionary spending declines in a potential downturn.
- Ongoing restructuring - including facility closures, workforce reductions and product changes like handing off Ground Saver to the U.S. Postal Service - carries execution risk until new cost baselines and volume mixes stabilize.